Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Eric J. Lowe"'
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Anaplastic large cell lymphoma (ALCL) is the most common type of mature T-cell non-Hodgkin lymphoma in children/adolescents. ALCL is characterized by expression of CD30 in the neoplastic lymphoid cells with frequent expression of anaplastic lymphoma
Externí odkaz:
https://doaj.org/article/51254447174646418da2d09917393909
Autor:
Eric J. Lowe, Anne F. Reilly, Megan S. Lim, Thomas G. Gross, Lauren Saguilig, Donald A. Barkauskas, Rui Wu, Sarah Alexander, Catherine M. Bollard
Publikováno v:
Journal of Clinical Oncology. 41:2043-2053
PURPOSE Arm crizotinib (CZ) of the Children's Oncology Group trial ANHL12P1 (ClinicalTrials.gov identifier: NCT01979536 ) examined the efficacy and toxicity of adding CZ to standard chemotherapy for children with newly diagnosed, nonlocalized ALK+ CD
Autor:
Lynley V. Marshall, Brenda J. Weigel, G. Lesa, Joe McDonough, Malcolm A. Smith, Gudrun Schleiermacher, Nick Bird, Franca Ligas, Elly Barry, Yael P. Mosse, D Valteau, Eric J. Lowe, Nicholas Richardson, François Doz, Meredith S. Irwin, Zachary Franklin Zimmerman, Toby Trahair, Koen Norga, Sonia Singh, Martha Donoghue, Steven G. DuBois, Susan L. Weiner, Michela Casanova, Giovanni Selvaggi, Andrew D.J. Pearson, Dominik Karres, Yousif Matloub, Keith D. Wilner, Teresa de Rojas, Nicole Scobie, Rajkumar Venkatramani, Gilles Vassal, H.N. Caron, Amar Gajjar, Amy Barone, Patricia Blanc, Margret Merino, Diana Bradford, Gregory H. Reaman, Willi Woessmann, Elizabeth Fox, Vickie Buenger, Julie Park, Karsten Nysom
Publikováno v:
European Journal of Cancer. 157:198-213
The first (2017) and sixth (2021) multistakeholder Paediatric Strategy Forums focused on anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. ALK is an important oncogene and target in several paediatric tumours (anaplastic large c
Publikováno v:
The Lancet. Oncology. 22(12)
Publikováno v:
British Journal of Haematology. 185:1043-1054
Anaplastic large cell lymphoma (ALCL) is a T cell Non-Hodgkin Lymphoma that mainly presents in paediatric and young adult patients. The majority of cases express a chimeric fusion protein resulting in hyperactivation of anaplastic lymphoma kinase (AL
Autor:
Donald A. Barkauskas, Eric J. Lowe, Sarah Alexander, Megan S. Lim, Catherine M. Bollard, Lauren Saguilig, Anne Reilly, Rui Wu, Thomas G. Gross
Publikováno v:
Blood. 137(26)
Approximately 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) relapse. Although brentuximab vedotin has demonstrated excellent activity in ALCL, it has not been used for newly diagnosed patients. Children’s Oncology Group (COG)
Autor:
Eric J. Lowe, Laurence Brugieres
Publikováno v:
Non-Hodgkin's Lymphoma in Childhood and Adolescence ISBN: 9783030117689
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c7a4e6f70e4057b768d2914c241c853
https://doi.org/10.1007/978-3-030-11769-6_20
https://doi.org/10.1007/978-3-030-11769-6_20
Autor:
Holly J. Edington, Eric J. Lowe
Publikováno v:
Journal of pediatric hematology/oncology. 41(3)
Monosomy 7 may be a poor prognostic indicator in pediatric myelodysplastic syndrome. There are case reports of children with monosomy 7 who undergo spontaneous remission 2 to 24 months after diagnosis. We report a case of a child with bone marrow fai
Autor:
Joseph Laver, James C. Lynch, Lynette M. Smith, Thomas G. Gross, Marsha C. Kinney, Sarah Alexander, Sheila Weitzman, Sherrie L. Perkins, Eric J. Lowe, Myron Chang, Jacqueline M. Kraveka, Howard J. Weinstein
Publikováno v:
Pediatric Blood & Cancer. 61:2236-2242
Background Optimal therapy for children and adolescents with advanced stage anaplastic large cell lymphoma (ALCL) is unknown. ANHL0131 examined whether a maintenance regimen including vinblastine compared to the standard APO (doxorubicin, prednisone,
Autor:
Eric J. Lowe, John T. Sandlund, David Hall, Catherine M. Bollard, Donald A. Barkauskas, Anne F. Reilly, Lauren Saguilig, Allen Buxton
Publikováno v:
Blood. 132:1625-1625
Background: Despite numerous treatment strategies, failure rates remain 25-30% for pediatric ALCL. Brentuximab vedotin is an antibody-drug conjugate containing an anti-CD30 monoclonal antibody linked to a tubulin inhibitor (monomethylauristatin E) wh